Anti-ox40 antibodies and uses thereof
By providing anti-OX40 antibodies or their antigen-binding fragments with unique CDR sequences, the problem of unclear efficacy of existing anti-OX40 antibodies in the treatment of human diseases has been solved, enabling effective treatment of OX40-related diseases, enhancing or inhibiting OX40 signal transduction, and improving the treatment efficacy of cancer, inflammation, and autoimmune diseases.
CN115461367BActive Publication Date: 2026-07-21HUTCHMED LIMITED
View PDF 15 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- HUTCHMED LIMITED
- Filing Date
- 2021-04-16
- Publication Date
- 2026-07-21
AI Technical Summary
Technical Problem
The efficacy of existing anti-OX40 antibodies in the treatment of human diseases is unclear, and no drugs have been approved yet, indicating a huge clinical need.
Method used
Anti-OX40 antibodies or their antigen-binding fragments with unique CDR sequences, including specific amino acid sequences of heavy and light chain variable regions, are provided for high-affinity binding to OX40 and can be used as agonists or antagonists for the treatment of tumor immunotherapy and autoimmune diseases.
Benefits of technology
It has achieved effective treatment of OX40-related diseases. By enhancing or inhibiting OX40 signal transduction, it has improved the therapeutic effects of cancer, inflammation, and autoimmune diseases, showing good tolerability and efficacy.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN115461367B_ABST
Abstract
The present disclosure provides anti-OX40 antibodies or antigen-binding fragments thereof, methods of making the same, and uses for treating OX40-related diseases or conditions.
Need to check novelty before this filing date? Find Prior Art